Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
J Clin Sleep MedAug 31, 2026 (epub)
Beverly Falcon, Cathy Chang Xie, Susan Redline et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of two Phase 3 randomized controlled trials evaluated the effects of tirzepatide on obstructive sleep apnea (OSA) measures in adults with moderate-to-severe OSA and obesity. Participants receiving tirzepatide showed significant reductions in the Apnea-Hypopnea Index (AHI) ranging from -27.7 to -34.1 events/h across various baseline characteristics, compared to placebo, which showed minimal changes.
Key findings
- Tirzepatide treatment resulted in AHI reductions of -27.7 to -34.1 events/h across different baseline subgroups.
- 68% to 79% of tirzepatide-treated participants improved in AHI severity category, compared to 64% to 70% in the placebo group.
- Improvements in body weight and systolic blood pressure were also observed with tirzepatide treatment.
Why it matters
Understanding the impact of tirzepatide on OSA-related measures can inform treatment strategies for patients with obesity and moderate-to-severe OSA, potentially leading to better management of this common disorder.